The European Parliament Wednesday voted overwhelmingly in favor of a draft law that would require member states to decide on the pricing and reimbursement of generic medicines within 60 days of an application.
EU Parliament members voted 559-54 in favor of the draft law, which is designed to speed up the availability of generic drugs. There were 72 abstentions. The legislation would revise the transparency rules for pricings and reimbursement of medicines, Directive 89/105/EEC, which have not been updated since 1989.
“It is unacceptable that delays in the pricing and reimbursement of medicines can sometimes reach more than 700 days,” Antonyia Parvanova, who is steering the legislation through Parliament, said. She must now negotiate an agreement with EU ministers.
The new legislation would leave the timeline for decisions concerning pricing of new drugs at 180 days. This decision drew criticism from the European Federation of Pharmaceuticals Industries and Associations (EFPIA). EFPIA wanted shorter maximum time limits for innovative drugs.
Being competitive means staying on top of changes in pharmaceutical regulations around the world. Whether your base is Australia, the United States, Jordan or Zimbabwe, you need to know how to remain a step ahead of your competitors.
Discover the FDAnews Guide to International Pharma Regulation: 2013 Edition. It’s the one-stop authority for quick, accurate answers to your questions. Rules change every day. So hold a world of regulatory expertise in your hands. Order your copy today!